ArticleUrology case reports2026
A rare case of multiple bladder hemangiomas associated with Glanzmann thrombasthenia: Successful control of refractory hematuria by super selective vesical artery embolization.
Article in Urology case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bladder hemangiomas are rare benign vascular tumors that may cause severe hematuria. We report a 66-year-old man with Glanzmann thrombasthenia who presented with life-threatening hematuria, clot retention, and severe anemia. Histopathological examination revealed multiple capillary bladder hemangiomas, while contrast-enhanced CT failed to clearly identify the lesions due to their small size. Despite intensive hematological support, including transfusions, recombinant activated factor VII, and transurethral electrocoagulation, bleeding recurred. Given the prohibitive hemorrhagic risk of repeat surgery, super selective vesical artery embolization was performed, achieving complete and durable hemostasis. No complications or recurrence occurred during six months of follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.